These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 25704226

  • 1. Safety and efficacy of 70-150 μm and 100-300 μm drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma.
    Deipolyi AR, Oklu R, Al-Ansari S, Zhu AX, Goyal L, Ganguli S.
    J Vasc Interv Radiol; 2015 Apr; 26(4):516-22. PubMed ID: 25704226
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.
    Prajapati HJ, Dhanasekaran R, El-Rayes BF, Kauh JS, Maithel SK, Chen Z, Kim HS.
    J Vasc Interv Radiol; 2013 Mar; 24(3):307-15. PubMed ID: 23375519
    [Abstract] [Full Text] [Related]

  • 3. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
    Dekervel J, van Malenstein H, Vandecaveye V, Nevens F, van Pelt J, Heye S, Laleman W, Van Steenbergen W, Vaninbroukx J, Verslype C, Maleux G.
    J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569
    [Abstract] [Full Text] [Related]

  • 4. Single-center comparison of three chemoembolization regimens for hepatocellular carcinoma.
    Petruzzi NJ, Frangos AJ, Fenkel JM, Herrine SK, Hann HW, Rossi S, Rosato EL, Eschelman DJ, Gonsalves CF, Brown DB.
    J Vasc Interv Radiol; 2013 Feb; 24(2):266-73. PubMed ID: 23261143
    [Abstract] [Full Text] [Related]

  • 5. Clinical and economic impact of drug eluting beads in transarterial chemoembolization for hepatocellular carcinoma.
    Vadot L, Boulin M, Guiu B, Aho LS, Vourc'h M, Musat A, Hillon P, Lepage C, Guignard MH, Fagnoni P.
    J Clin Pharm Ther; 2015 Feb; 40(1):83-90. PubMed ID: 25413186
    [Abstract] [Full Text] [Related]

  • 6. Transarterial hepatic chemoembolization with 70-150 µm drug-eluting beads: assessment of clinical safety and liver toxicity profile.
    Odisio BC, Ashton A, Yan Y, Wei W, Kaseb A, Wallace MJ, Vauthey JN, Gupta S, Tam AL.
    J Vasc Interv Radiol; 2015 Jul; 26(7):965-71. PubMed ID: 25979305
    [Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of drug-eluting bead chemoembolization for hepatocellular carcinoma: comparison of small-versus medium-size particles.
    Padia SA, Shivaram G, Bastawrous S, Bhargava P, Vo NJ, Vaidya S, Valji K, Harris WP, Hippe DS, Kogut MJ.
    J Vasc Interv Radiol; 2013 Mar; 24(3):301-6. PubMed ID: 23380737
    [Abstract] [Full Text] [Related]

  • 8. Conventional versus Drug-Eluting Bead Transarterial Chemoembolization for Neuroendocrine Tumor Liver Metastases.
    Makary MS, Kapke J, Yildiz V, Pan X, Dowell JD.
    J Vasc Interv Radiol; 2016 Sep; 27(9):1298-1304. PubMed ID: 27499157
    [Abstract] [Full Text] [Related]

  • 9. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
    Prajapati HJ, Xing M, Spivey JR, Hanish SI, El-Rayes BF, Kauh JS, Chen Z, Kim HS.
    AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
    [Abstract] [Full Text] [Related]

  • 10. Superselective Chemoembolization of HCC: Comparison of Short-term Safety and Efficacy between Drug-eluting LC Beads, QuadraSpheres, and Conventional Ethiodized Oil Emulsion.
    Duan F, Wang EQ, Lam MG, Abdelmaksoud MH, Louie JD, Hwang GL, Kothary N, Kuo WT, Hofmann LV, Sze DY.
    Radiology; 2016 Feb; 278(2):612-21. PubMed ID: 26334787
    [Abstract] [Full Text] [Related]

  • 11. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma.
    Niessen C, Unterpaintner E, Goessmann H, Schlitt HJ, Mueller-Schilling M, Wohlgemuth WA, Stroszczynski C, Wiggermann P.
    J Vasc Interv Radiol; 2014 Feb; 25(2):240-7. PubMed ID: 24291001
    [Abstract] [Full Text] [Related]

  • 12. Idarubicin-loaded ONCOZENE drug-eluting embolic agents for chemoembolization of hepatocellular carcinoma: in vitro loading and release and in vivo pharmacokinetics.
    Guiu B, Schmitt A, Reinhardt S, Fohlen A, Pohl T, Wendremaire M, Denys A, Blümmel J, Boulin M.
    J Vasc Interv Radiol; 2015 Feb; 26(2):262-70. PubMed ID: 25311967
    [Abstract] [Full Text] [Related]

  • 13. Transarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: Now and future.
    Woo HY, Heo J.
    Clin Mol Hepatol; 2015 Dec; 21(4):344-8. PubMed ID: 26770921
    [Abstract] [Full Text] [Related]

  • 14. Predicting Treatment Response to Intra-arterial Therapies for Hepatocellular Carcinoma with the Use of Supervised Machine Learning-An Artificial Intelligence Concept.
    Abajian A, Murali N, Savic LJ, Laage-Gaupp FM, Nezami N, Duncan JS, Schlachter T, Lin M, Geschwind JF, Chapiro J.
    J Vasc Interv Radiol; 2018 Jun; 29(6):850-857.e1. PubMed ID: 29548875
    [Abstract] [Full Text] [Related]

  • 15. Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results.
    de Baere T, Deschamps F, Teriitheau C, Rao P, Conengrapht K, Schlumberger M, Leboulleux S, Baudin E, Hechellhammer L.
    J Vasc Interv Radiol; 2008 Jun; 19(6):855-61. PubMed ID: 18503899
    [Abstract] [Full Text] [Related]

  • 16. Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.
    Shuster A, Huynh TJ, Rajan DK, Marquez MA, Grant DR, Huynh DC, Jaskolka JD.
    J Vasc Interv Radiol; 2013 Jun; 24(6):805-12. PubMed ID: 23562641
    [Abstract] [Full Text] [Related]

  • 17. Safety and feasibility of same-day discharge of patients with hepatocellular carcinoma treated with transarterial chemoembolization with drug-eluting beads in a liver transplantation program.
    Nasser F, Cavalcante RN, Galastri FL, de Rezende MB, Felga GG, Travassos FB, De Fina B, Affonso BB.
    J Vasc Interv Radiol; 2014 Jul; 25(7):1012-7. PubMed ID: 24704346
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of the relationship between hepatocellular carcinoma location and transarterial chemoembolization efficacy.
    Miki I, Murata S, Uchiyama F, Yasui D, Ueda T, Sugihara F, Saito H, Yamaguchi H, Murakami R, Kawamoto C, Uchida E, Kumita SI.
    World J Gastroenterol; 2017 Sep 21; 23(35):6437-6447. PubMed ID: 29085193
    [Abstract] [Full Text] [Related]

  • 19. Chemoembolization of hepatocellular carcinoma with HepaSphere 30-60 μm. Safety and efficacy study.
    Malagari K, Pomoni M, Moschouris H, Kelekis A, Charokopakis A, Bouma E, Spyridopoulos T, Chatziioannou A, Sotirchos V, Karampelas T, Tamvakopoulos C, Filippiadis D, Karagiannis E, Marinis A, Koskinas J, Kelekis DA.
    Cardiovasc Intervent Radiol; 2014 Feb 21; 37(1):165-75. PubMed ID: 24263774
    [Abstract] [Full Text] [Related]

  • 20. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.
    Pinter M, Hucke F, Graziadei I, Vogel W, Maieron A, Königsberg R, Stauber R, Grünberger B, Müller C, Kölblinger C, Peck-Radosavljevic M, Sieghart W.
    Radiology; 2012 May 21; 263(2):590-9. PubMed ID: 22438359
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.